LBB to supply Meggle’s excipients in the US market

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Stuart Ritchie)
(Image: Getty/Stuart Ritchie)

Related tags: Excipients, Excipient, Meggle Excipients & Technology, inhalation products

LBB takes on the marketing and distribution of Meggle’s lactose-based excipients for direct compression and inhalation in the US market.

New York-based company, LBB Specialties, through its subsidiaries Charkit Chemical and American International Chemical (AIC), has entered a partnership with Meggle Excipients & Technology, a pharmaceutical excipients manufacturer based in Wasserburg, Germany.

Under the partnership, Charkit and AIC will share responsibility for sales, marketing and distribution in the US market of Meggle’s lactose-based excipients, used for direct compression and granulation tableting, powder preparations and dry powder inhalation.

Jay Lang, president of Charkit, commented that Meggle is “one of only a handful of manufacturers of pharma-grade lactose excipients in the world”​, adding that its products are of ‘excellent’ quality.

Meggle’s Excipients & Technology business group produces pharmaceutical excipients for capsules, sachets, powder blends and dry powder inhalers and holds production facilities in Germany and Minnesota, US.

The partnership between Meggle and LBB began August 1, 2019.

Expanding in a booming market

The pharmaceutical excipients market​ in the US is currently worth an estimated $2.1bn (€1.9bn), and is projected to grow by 5.1% year-over-year over the next five years.

The rising uptake of biopharmaceuticals which require advanced formulation ingredients, as well as the increasing adoption of orphan drug products with multifunctional excipients, is expected to further boost the market’s growth in the foreseeable future.

Additionally, the patent expiration of several blockbuster drugs will open the possibility for the introduction of generics, such as in the case of Pfizer’s Lyrica​ (pregabalin) and the most recent example of Eli Lilly’s Alimta​ (pemetrexed), for which the patents expire in 2022, with Mylan’s generic drug product having already seen tentative approval.

Related news

Show more

Related product

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us


View more